AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder ...

Mr. Connor and his team at Vanderbilt designed, manufactured, and evaluated a stone retrieval device with an independently ...

The responder rate, calculated as the proportion of subjects with ≥ 30% improvement in IPSS, was 74% at 36 months, similar to 75% at 12 months and 70% at 24 months. No deterioration in erectile or ...

Stabilized hyaluronic acid is increasingly used as a rectal spacer to reduce radiation related gastrointestinal side effects in prostate cancer treatment. Rectal wall infiltration is uncommon but a ...

To compensate for tissue displacement when the needle is fired, the novel biopsy gun is designed to cause the needle to recoil twice when it reaches the end of its travel. A second feature delays ...

Notably, data from the National Trauma Data Bank (NTDB) show that nearly 50% of extraperitoneal injuries underwent repair between 2002–2006—highlighting that clinical judgment frequently supports ...

Patients treated with darolutamide who reached ultra-low PSA at any time had lower risk of radiological progression or death versus those with PSA >=0.2 ng/mL, with a risk reduction of 91%, as did ...

(UroToday.com) Dr. Federico Zorzi presented his research on the potential of arteriogenic insufficiency assessed by penile doppler ultrasound as a predictor for major cardiovascular (CV) events in ...

(UroToday.com) The Sunday Plenary at the AUA 2025 Annual Meeting in Las Vegas included a panel discussion on “Challenging Cases in Recurrent Urinary Tract Infections,” featuring experts in urology and ...

Specifically, 16% of men and 5% of women had PVRs greater than 150 mL. “ That kind of goes against what we tend to expect as urologists ,” she added, noting that patients with long-standing type 1 ...

Dr. Ben-David began his presentation by highlighting that tumor-informed circulating tumor DNA (ctDNA) has emerged as a novel prognostic biomarker in bladder cancer. His team sought to evaluate ...

Oncologic Outcomes in Patients Undergoing Radical Cystectomy for non–muscle-invasive bladder cancer (NMIBC) Following BCG Therapy Failure. Dr. Oberneder highlighted that the U.S. FDA has approved ...